Erasca (ERAS) announced a clinical trial collaboration and supply agreement with Merck (MRK). This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with RAS-mutant solid tumors. Erasca is sponsoring the study, and Merck is supplying pembrolizumab at no cost.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS: